Welcome to our dedicated page for Werewolf Therapeutics news (Ticker: HOWL), a resource for investors and traders seeking the latest updates and insights on Werewolf Therapeutics stock.
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) is a clinical-stage biopharmaceutical company pioneering conditionally activated immunotherapies for cancer treatment. This news hub provides investors and industry observers with essential updates on the company’s innovative pipeline, including its INDUKINE molecules WTX-330 and WTX-124 developed through the proprietary PREDATOR platform.
Access real-time announcements covering clinical trial progress, regulatory milestones, financial results, and strategic partnerships. Our curated collection ensures you stay informed about developments in immuno-oncology therapies designed to activate only within tumor microenvironments – a breakthrough approach aiming to improve safety profiles compared to traditional cytokine treatments.
Key updates include phase 1/2 trial data readouts, IND applications, collaboration agreements, and peer-reviewed research publications. All content is vetted for relevance to investment analysis and therapeutic advancement in solid tumors and immune-mediated diseases.
Bookmark this page for streamlined tracking of HOWL’s scientific and corporate developments. Combine our news feed with Stock Titan’s financial tools to monitor this innovator’s progress in redefining cancer immunotherapy.
Werewolf Therapeutics (NASDAQ: HOWL) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical trials. The company expects full enrollment in cutaneous melanoma dose-expansion arms of the WTX-124 Phase 1/1b trial by H2 2025, with interim data release planned for Q4 2025.
Key financial metrics show cash and cash equivalents of $111.0 million as of December 31, 2024, expected to fund operations through Q2 2026. The company reported a net loss of $70.5 million for full year 2024, compared to $37.4 million in 2023. Research and development expenses increased to $56.4 million in 2024 from $41.8 million in 2023.
Clinical highlights include promising preliminary evidence of durable anti-tumor activity for WTX-124, with five objective responses reported. The company plans to meet with the FDA in H2 2025 to discuss potential registrational pathways. Additionally, Werewolf is on track to initiate a Phase 1/2 trial for WTX-330 by the end of Q1 2025.
Werewolf Therapeutics (Nasdaq: HOWL), a biopharmaceutical company focused on developing conditionally activated therapeutics for cancer treatment and immune-mediated conditions, has announced its participation in the upcoming 2025 Leerink Partners Global Biopharma Conference.
The company's leadership, including Daniel J. Hicklin, Ph.D., President and CEO, and Randi Isaacs, M.D., Chief Medical Officer, will engage in a fireside chat scheduled for Tuesday, March 11, 2025, from 11:20-11:50 AM in Studio 3. The conference will take place in Miami, Florida, from March 10-12, 2025.
Interested parties can access a live webcast of the presentation through the company's investor relations website. The recorded session will remain available for replay for 180 days following the event.
Werewolf Therapeutics (Nasdaq: HOWL) has announced the appointment of Anil Singhal, Ph.D., President and CEO of Trishula Therapeutics, to its board of directors. Dr. Singhal brings over 30 years of oncology research and development leadership experience to HOWL's board. He previously served as President and CEO of Adicet Bio, where he led the company to its first oncology IND submission and merger with resTOR bio.
The appointment coincides with the planned resignation of Derek DiRocco from the board, effective at the company's 2025 annual meeting of stockholders. DiRocco has served on the board since joining during the Series B funding round led by RA Capital in 2020.
Werewolf Therapeutics focuses on developing conditionally activated therapeutics using its PREDATOR protein engineering platform to stimulate the immune system for treating cancer and immunological diseases.
Werewolf Therapeutics (Nasdaq: HOWL) has provided a business update and strategic outlook for 2025. Key highlights include:
WTX-124: Data from Phase 1/1b clinical trials evaluating WTX-124 as a monotherapy is expected in the first half of 2025. Data from trials in combination with pembrolizumab is anticipated in Q4 2025. These results will guide regulatory engagements for potential registrational pathways. The recommended dose for monotherapy expansion arms has been set at 18 mg IV Q2W for metastatic melanoma, RCC, and CSCC, and for combination expansion arms in metastatic melanoma, RCC, and NSCLC.
WTX-330: Initiation of a Phase 1/2 dose- and regimen-finding clinical trial is expected in Q1 2025. This trial aims to optimize delivery to the tumor microenvironment and may open expansion arms in selected tumor types pending data.
Preclinical Portfolio: Development candidates include WTX-712 (IL-21 INDUKINE), WTX-518 (IL-18 INDUKINE), and WTX-921 (IL-10 INDUKINE). Werewolf plans to complete pre-clinical work and seek strategic partnerships to advance these programs in 2025.
Financial Guidance: Werewolf expects its cash and cash equivalents to fund operational expenses through at least Q2 2026.
Werewolf Therapeutics (Nasdaq: HOWL), a biopharmaceutical company focused on developing conditionally activated therapeutics for cancer treatment, has announced its participation in the 7th Annual Evercore ISI HealthCONx Healthcare Conference. Daniel J. Hicklin, Ph.D., President and CEO, and Randi Isaacs, M.D., Chief Medical Officer, will engage in a fireside chat on December 5, 2024, at 12:55 pm ET in Miami, Florida. The conference runs from December 3-5, and a live webcast will be available on the company's investor website, with a replay accessible for approximately 90 days after the event.
Werewolf Therapeutics (HOWL) presented interim Phase 1 clinical trial results for WTX-330, their tumor-activated IL-12 prodrug, at SITC's 39th Annual Meeting. The trial enrolled 25 patients with diverse solid tumors, showing favorable tolerability and encouraging efficacy. Key findings include a confirmed partial response in a melanoma patient and evidence of tumor immune activation in MSS CRC patients. WTX-330 demonstrated 22-fold greater plasma exposure compared to rhIL-12, with low active IL-12 levels. The company plans to initiate a Phase 1/2 dose-finding trial in H1 2025. Additional preclinical data showed promising results for INDUKINE molecules with various cytokines.
Werewolf Therapeutics (HOWL) reported Q3 2024 financial results and provided updates on its clinical pipeline. The company reported a net loss of $16.7 million with cash and equivalents of $122.8 million, providing runway through Q2 2026. Key developments include ongoing Phase 1/1b trials of WTX-124 and WTX-330, with initial efficacy data expected in H1 2025. The company introduced WTX-921, a new IL-10 INDUKINE molecule for inflammatory diseases. Clinical trials showed promising results, including confirmed partial responses in melanoma patients and a complete response in an advanced CSCC patient that has remained in remission for over twelve months.
Werewolf Therapeutics (Nasdaq: HOWL) has announced WTX-921, a novel IL-10 INDUKINE development candidate for Inflammatory Bowel Disease (IBD) and other inflammatory diseases. This expansion leverages their PREDATOR® platform technology, which has shown promising safety and efficacy in oncology trials. The platform enables conditional activation of cytokines specifically in disease tissues while protecting healthy tissues. WTX-921 represents the company's strategic move beyond oncology into inflammatory diseases, targeting IBD which affects approximately 0.7% of Americans (721 cases per 100,000 people). The development addresses a significant unmet medical need, as IBD currently has no cure, only symptom management options.
Werewolf Therapeutics (Nasdaq: HOWL) announced it will present two posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting in Houston, Texas, from November 6-10, 2024. The first poster, titled 'INDUKINE™ Molecules Delivering Various Cytokines Utilize Unique Mechanisms of Action to Drive Anti-Tumor Efficacy in Murine Syngeneic Tumor Models' (Abstract 955), will be presented on November 8. The second poster, 'The tumor-activated IL-12 prodrug WTX-330 expanded/activated tumor infiltrating lymphocytes and caused tumor regression in patients with refractory solid tumors: Interim data from an ongoing Ph1 study' (Abstract 672), will be presented on November 9.
Both presentations will take place at the George R. Brown Convention Center - Exhibit Halls A B. Werewolf Therapeutics is a biopharmaceutical company focused on developing conditionally activated therapeutics to stimulate the immune system for cancer treatment.
Werewolf Therapeutics (Nasdaq: HOWL), a biopharmaceutical company developing conditionally activated therapeutics for cancer treatment, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York City.
Key details:
- Daniel J. Hicklin, Ph.D., President and CEO, and Randi Isaacs, M.D., Chief Medical Officer, will participate in a fireside chat
- The presentation is set for September 10, 2024, at 11:00 am ET
- A webcast link will be available on the company's investor relations website
- An archived replay will be accessible for approximately 90 days after the event
This conference provides Werewolf Therapeutics an opportunity to showcase its innovative approach to cancer immunotherapy and engage with potential investors.
FAQ
What is the current stock price of Werewolf Therapeutics (HOWL)?
What is the market cap of Werewolf Therapeutics (HOWL)?
